Gene therapy and cement injection for restabilization of loosened hip prostheses

Human Gene Therapy

Volumn 19, Issue 1, 2008, Pages 83-95

  De Poorter, Jolanda J ^a   Hoeben, Rob C ^a   Hogendoorn, Simone ^a   Mautner, Vivien ^b   Ellis, John ^c   Obermann, Wim R ^a   Huizinga, Tom W J ^a   Nelissen, Rob G H H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Innovata PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BONE CEMENT; PRODRUG; VIRUS VECTOR;

ADENOVIRUS; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ELDERLY CARE; FEMALE; GASTROINTESTINAL TOXICITY; GENE THERAPY; GENE TRANSFER; HIP PROSTHESIS; HUMAN; HYPONATREMIA; HYPOTENSION; JOINT STABILITY; KIDNEY FAILURE; LIVER TOXICITY; MALE; MINIMALLY INVASIVE SURGERY; NAUSEA AND VOMITING; NEEDLE BIOPSY; OSTEOARTHRITIS; PAIN; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTHESIS LOOSENING; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; UTERUS CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; X RAY;

AGED; BONE CEMENTS; CEMENTATION; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; HIP FRACTURES; HIP PROSTHESIS; HUMANS; INJECTIONS; MALE; PROSTHESIS DESIGN;

EID: 38649098120     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.111     Document Type: Article

References (28)

1. BOHM, P., and BISCHEL, O. (2001). Femoral revision with the Wagner SL revision stem: Evaluation of one hundred and twenty-nine revisions followed for a mean of 4.8 years. J. Bone Joint Surg. Am. 83, 1023-1031.
2. BRAMSON, J.L., HITT, M., GAULDIE, J., and GRAHAM, F.L. (1997). Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4, 1069-1076.
3. BRIDGEWATER, J.A., SPRINGER, C.J., KNOX, R.J., MINTON, N.P., MICHAEL, N.P., and COLLINS, M.K. (1995). Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370 [erratum in Eur. J. Cancer 1996;32A:186].
4. CHUNG-FAYE, G., PALMER, D., ANDERSON, D., CLARK, J., DOWNES, M., BADDELEY, J., HUSSAIN, S., MURRAY, P.I., SEARLE, P., SEYMOUR, L., HARRIS, P.A., FERRY, D., and KERR, D.J. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7, 2662-2668.
5. DE POORTER, J.J., TOLBOOM, T.C., RABELINK, M.J., PIETERMAN, E., HOEBEN, R.C., NELISSEN, R.G., and HUIZINGA, T.W. (2005). Towards gene therapy in prosthesis loosening: Efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. J. Gene Med. 7, 1421-1428.
6. DJEHA, A.H., THOMSON, T.A., LEUNG, H., SEARLE, P.F., YOUNG, L.S., KERR, D.J., HARRIS, P.A., MOUNTAIN, A., and WRIGHTON, C.J. (2001). Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol. Ther. 3, 233-240.
7. ECHAVARRIA, M., FORMAN, M., TICEHURST, J., DUMLER, J.S., and CHARACHE, P. (1998). PCR method for detection of adenovirus in urine of healthy and human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 36, 3323-3326.
8. FALLAUX, F.J., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
9. GOLDRING, S.R., SCHILLER, A.L., ROELKE, M., ROURKE, C.M., O'NEILL, D.A., and HARRIS, W.H. (1983). The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J. Bone Joint Surg. Am. 65, 575-584.
10. GOOSSENS, P.H., SCHOUTEN, G.J., 'T HART, B.A., BOUT, A., BROK, H.P., KLUIN, P.M., BREEDVELD, F.C., VALERIO, D., and HUIZINGA, T.W. (1999). Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum. Gene Ther. 10, 1139-1149.
11. GOOSSENS, P.H., VOGELS, R., PIETERMAN, E., HAVENGA, M.J., BOUT, A., BREEDVELD, F.C., VALERIO, D., and HUIZINGA, T.W. (2001). The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum. 44, 48-52.
12. GREENWALD, A.S., NARTEN, N.C., and WILDE, A.H. (1978). Points in the technique of recementing in the revision of an implant arthroplasty. J. Bone Joint Surg. Br. 60, 107-110.
13. GRUEN, T.A., MCNEICE, G.M., and AMSTUTZ, H.C. (1979). "Modes of failure" of cemented stem-type femoral components: A radiographic analysis of loosening. Clin. Orthop. Relat. Res. 141, 17-27.
14. HARRIS, W.H. (1969). Traumatic arthritis of the hip after dislocation and acetabular fractures: Treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J. Bone Joint Surg. Am. 51, 737-755.
15. HENAO, F.J., DAES, J.E., and DENNIS, R.J. (1991). Risk factors for multiorgan failure: A case-control study. J. Trauma 31, 74-80.
16. KNOX, R.J., JENKINS, T.C., HOBBS, S.M., CHEN, S., MELTON, R.G., and BURKE, P.J. (2000). Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: A novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 60, 4179-4186.
17. LIEBERMAN, J.R., MOECKEL, B.H., EVANS, B.G., SALVATI, E.A., and RANAWAT, C.S. (1993). Cement-within-cement revision hip arthroplasty. J. Bone Joint Surg. Br. 75, 869-871.
18. LIEBERMAN, J.R., DOREY, F., SHEKELLE, P., SCHUMACHER, L., THOMAS, B.J., KILGUS, D.J., and FINERMAN, G.A. (1996). Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. J. Bone Joint Surg. Am. 78, 835-838.
19. LIPINSKI, K.S., PELECH, S., MOUNTAIN, A., IRVINE, A.S., KRAAIJ, R., BANGMA, C.H., MILLS, K.H., and TODRYK, S.M. (2006). Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol. Immunother. 55, 347-354.
20. MAHOMED, N.N., BARRETT, J.A., KATZ, J.N., PHILLIPS, C.B., LOSINA, E., LEW, R.A., GUADAGNOLI, E., HARRIS, W.H., POSS, R., and BARON, J.A. (2003). Rates and outcomes of primary and revision total hip replacement in the United States Medicare population. J. Bone Joint Surg. Am. 85, 27-32.
21. MALCHAU, H. (2000). Prognosis of total hip replacement: Update and validation of results from the Swedish National Hip Arthroplasty Registry 1979-1998. Presented at 67th Annual Meeting of the American Academy of Orthopedic surgeons, March 15-19, 2000, Orlando, FL.
22. MCGEE, M.A., HOWIE, D.W., RYAN, P., MOSS, J.R., and HOLUBOWYCZ, O.T. (2002). Comparison of patient and doctor responses to a total hip arthroplasty clinical evaluation questionnaire. J. Bone Joint Surg. Am. 84, 1745-1752.
23. PALMER, D.H., MAUTNER, V., MIRZA, D., OLIFF, S., GERRITSEN, W., VAN DER SIJP, J.R., HUBSCHER, S., REYNOLDS, G., BONNEY, S., RAJARATNAM, R., HULL, D., HORNE, M., ELLIS, J., MOUNTAIN, A., HILL, S., HARRIS, P.A., SEARLE, P.F., YOUNG, L.S., JAMES, N.D., and KERR, D.J. (2004). Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 22, 1546-1552.
24. ROBERTS, J.J., FRIEDLOS, F., and KNOX, R.J. (1986). CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 140, 1073-1078.
25. STREHLE, J., DELNOTARO, C., ORLER, R., and ISLER, B. (2000). The outcome of revision hip arthroplasty in patients older than age 80 years: Complications and social outcome of different risk groups. J. Arthroplasty 15, 690-697.
26. VACANTI, C.J., VANHOUTEN, R.J., and HILL, R.C. (1970). A statistical analysis of the relationship of physical status to postoperative mortality in 68,388 cases. Anesth. Analg. 49, 564-566.
27. WEEDON, S.J., GREEN, N.K., MCNEISH, I.A., GILLIGAN, M.G., MAUTNER, V., WRIGHTON, C.J., MOUNTAIN, A., YOUNG, L.S., KERR, D.J., and SEARLE, P.F. (2000). Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 86, 848-854.
28. WHO Handbook for Reporting Results of Cancer Treatments. (1979). WHO, Geneva. pp. 1-45.